Associations between seizures and MRI in patients with anti-NMDAR encephalitis

Guanzhong Ni1,2, Wanrong Lin3, Xiaodong Cai4

  • 1Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.

Abstract

Insights

In anti-N-methyl-d-aspartate receptor (anti-NMDAR) encephalitis, abnormal MRI findings correlate with focal seizures. Despite initial seizure control differences, abnormal MRI does not impact long-term prognosis in these patients.

Area of Science:

  • Neurology
  • Neuroimmunology
  • Neuroradiology

Background:

  • Anti-N-methyl-d-aspartate receptor (anti-NMDAR) encephalitis is an autoimmune disorder frequently presenting with seizures.
  • Brain magnetic resonance imaging (MRI) abnormalities are common but their association with seizure characteristics and outcomes is not fully understood.

Purpose of the Study:

  • To investigate the relationship between seizure characteristics and brain MRI findings in patients diagnosed with anti-NMDAR encephalitis.
  • To assess how MRI findings influence seizure control and long-term outcomes in anti-NMDAR encephalitis.

Main Methods:

  • Retrospective analysis of 35 patients with anti-NMDAR encephalitis from January 2015 to December 2018.
  • Patients were categorized into normal and abnormal brain MRI groups.
  • Seizure types, treatment, and modified Rankin Scale scores at 1-year follow-up were compared between groups.

Main Results:

  • Eighty percent of patients experienced seizures during the acute phase.
  • Abnormal MRI findings were associated with a higher incidence of focal seizures (72.7% vs 17.6%) and shorter onset-to-immunotherapy time.
  • No significant differences in 1-year seizure outcomes were observed between MRI groups.

Conclusions:

  • Focal seizures are more prevalent in anti-NMDAR encephalitis patients with abnormal MRI lesions.
  • Patients with abnormal MRI may achieve quicker seizure control in the acute stage.
  • Abnormal MRI findings do not adversely affect the overall favorable prognosis of anti-NMDAR encephalitis patients with seizures.